BioLineRx (NASDAQ:BLRX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $21.00 target price on the biotechnology company’s stock.

Separately, StockNews.com upgraded shares of BioLineRx to a sell rating in a research report on Friday, April 12th.

BioLineRx Stock Performance

NASDAQ BLRX opened at $0.62 on Wednesday. The company has a quick ratio of 1.47, a current ratio of 1.53 and a debt-to-equity ratio of 0.50. BioLineRx has a 52-week low of $0.61 and a 52-week high of $2.53. The business’s 50-day moving average price is $1.08 and its 200 day moving average price is $1.34. The firm has a market cap of $49.74 million, a P/E ratio of -0.69 and a beta of 1.38.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The company had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same period in the prior year, the business earned ($0.09) EPS. On average, equities research analysts expect that BioLineRx will post -1.03 earnings per share for the current year.

Institutional Investors Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently modified their holdings of BLRX. Renaissance Technologies LLC increased its stake in shares of BioLineRx by 278.0% during the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 189,678 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new position in shares of BioLineRx during the 1st quarter worth approximately $178,000. Envestnet Asset Management Inc. purchased a new position in shares of BioLineRx during the 1st quarter worth approximately $88,000. LPL Financial LLC increased its stake in shares of BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 71,134 shares in the last quarter. Finally, PVG Asset Management Corp purchased a new position in shares of BioLineRx during the 4th quarter worth approximately $97,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.